Kansas City - New Vaccine Surveillance Network (KC-NVSN)
Project Number5U01IP001057-02
Contact PI/Project LeaderSELVARANGAN, RANGARAJ Other PIs
Awardee OrganizationCHILDREN'S MERCY HOSP (KANSAS CITY, MO)
Description
Abstract Text
Project Summary:
The Kansas City-New Vaccine Surveillance Network (KC-NVSN) program was established in 2009 to conduct
population-based, laboratory-confirmed, active surveillance of acute gastroenteritis (AGE) illness in children
seeking care at Children's Mercy Hospital, in Kansas City (KC), MO. The program was subsequently expanded
in 2015 to include hospitalized ARI children in inpatient (IP) settings.
In the current proposal, the KC-NVSN program seeks to continue the existing pediatric AGE IP and outpatient
(OP) surveillance in the six county KC metropolitan area and ARI IP surveillance in Jackson County, MO. In
addition, we will expand ARI surveillance to OP from Jackson County visiting the main CMH emergency
department. Age and time matched healthy control children will also be enrolled. Eligible children visiting or
admitted to our hospital system as defined above will be enrolled using permission and assent forms approved
by the institutional review board (IRB) of CMH. We will conduct parent interviews, collect medical chart data
and retrieve hard copies of vaccine information for influenza and rotavirus from enrolled children. Clinical
specimens collected from children will be tested for rotavirus (and other GI pathogens, e.g. norovirus in
proposed subprojects) in stool and 22 respiratory pathogens from respiratory specimen including specific
influenza subtypes and other non-influenza viruses, such as RSV, EV-D68 etc. The data collected from the
KC-NVSN program will provide population-based estimates to address the following specific aims:
1. To assess vaccine effectiveness (VE) in preventing medically attended rotavirus and influenza
illness by the test-negative case-control study design using laboratory confirmed testing among
enrolled children.
2. To assess the burden of select AGE pathogens and non-influenza viral pathogens, including
respiratory syncytial virus and EV-D68 among enrolled children.
The KC-NVSN program will provide data to be combined with other geographically diverse sites to estimate the
national incidence, burden, and etiology of community-acquired AGE and ARI. The VE for rotavirus and
seasonal influenza vaccinations will be calculated to measure the impact of vaccination. This network will also
address several important scientific questions related to natural history of pediatric infectious diseases,
transmission dynamics, impact of vaccine on targeted and vulnerable population and factors that influence
vaccine effectiveness. The surveillance data generated from this network will provide timely and highly useful
data to inform public health measures and pediatric vaccine-related policies aimed at controlling AGE and ARI
in US children.
Public Health Relevance Statement
Project Narrative:
The Kansas City-New Vaccine Surveillance Network site proposes to conduct surveillance for children with
diarrheal and respiratory illness seeking care at emergency department or admitted to Children's Mercy
Hospital, Kansas City, MO, for next five years. The goal of the project is to detect the infectious causes of
respiratory illnesses, and diarrhea and vomiting in children to determine the burden of these diseases and
assess the effectiveness of licensed/upcoming vaccines against them. The protection offered by rotavirus and
influenza vaccines will be measured by assessing vaccine receipt and infection status of the children. Burden
of norovirus, RSV and EV-D68 will also be monitored to inform public health authorities on priorities and
policies relating to vaccine development and prevention of these infections in children. Additional studies to
understand the spread of disease and identify population at high risk for severe infection or serious
complications will also be undertaken. This network will provide timely and highly useful data for public health
interventions against these diseases in children.
National Center for Immunization and Respiratory Diseases
CFDA Code
185
DUNS Number
073067480
UEI
N52NHWMBZNG5
Project Start Date
01-September-2016
Project End Date
31-August-2021
Budget Start Date
01-September-2017
Budget End Date
31-August-2018
Project Funding Information for 2017
Total Funding
$1,000,000
Direct Costs
$800,000
Indirect Costs
$200,000
Year
Funding IC
FY Total Cost by IC
2017
National Center for Immunization and Respiratory Diseases
$1,000,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U01IP001057-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U01IP001057-02
Patents
No Patents information available for 5U01IP001057-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U01IP001057-02
Clinical Studies
No Clinical Studies information available for 5U01IP001057-02
News and More
Related News Releases
No news release information available for 5U01IP001057-02
History
No Historical information available for 5U01IP001057-02
Similar Projects
No Similar Projects information available for 5U01IP001057-02